论文部分内容阅读
尼非卡兰(Nifekalant)是国内新上市的一种Ⅲ类抗心律失常药物,与其他Ⅲ类抗心律失常药物(胺碘酮、索他洛尔等)的药理学有明显不同。尼非卡兰是一种单纯的钾离子通道阻滞剂,只作用于I_(Kr)通道,对Ca~(2+)通道及β受体无作用,因而没有负性变力作用,不影响心功能,也不引起低血压和心动过缓。其可有效延长心房和心室肌细胞的动作电位时程(APD)和不应期。尼非卡兰在国内批准应用的适应证为“用于
Nifekalant is a newly marketed class III antiarrhythmic drug that is significantly different from the pharmacology of other class III antiarrhythmic drugs (amiodarone, sotalol, etc.). Neftekalan is a simple potassium channel blocker that acts only on the I_ (Kr) channel and has no effect on the Ca_ (2+) channel and the β receptor, so it does not negatively deactivate and does not affect Heart function does not cause hypotension and bradycardia. It can effectively prolong the action potential duration (APD) and refractory period of atrial and ventricular myocytes. The indications for the approval of the use of Neftechaur in the country are ”used"